Candel Therapeutics (CADL) Competitors $5.24 -0.12 (-2.24%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CADL vs. AUPH, WVE, NAGE, MLYS, RCUS, SYRE, AKBA, CVAC, ELVN, and PAHCShould you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Niagen Bioscience (NAGE), Mineralys Therapeutics (MLYS), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), CureVac (CVAC), Enliven Therapeutics (ELVN), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Candel Therapeutics vs. Its Competitors Aurinia Pharmaceuticals Wave Life Sciences Niagen Bioscience Mineralys Therapeutics Arcus Biosciences Spyre Therapeutics Akebia Therapeutics CureVac Enliven Therapeutics Phibro Animal Health Aurinia Pharmaceuticals (NASDAQ:AUPH) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation. Which has higher valuation & earnings, AUPH or CADL? Candel Therapeutics has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Candel Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurinia Pharmaceuticals$247.30M4.44-$78.02M$0.2829.05Candel Therapeutics$120K2,187.83-$37.94M-$1.34-3.91 Does the MarketBeat Community favor AUPH or CADL? Aurinia Pharmaceuticals received 560 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 65.38% of users gave Candel Therapeutics an outperform vote. CompanyUnderperformOutperformAurinia PharmaceuticalsOutperform Votes57773.41% Underperform Votes20926.59% Candel TherapeuticsOutperform Votes1765.38% Underperform Votes934.62% Does the media prefer AUPH or CADL? In the previous week, Aurinia Pharmaceuticals had 6 more articles in the media than Candel Therapeutics. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 2 mentions for Candel Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.44 beat Candel Therapeutics' score of 1.31 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AUPH or CADL more profitable? Candel Therapeutics has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aurinia Pharmaceuticals-10.23% -4.41% -3.07% Candel Therapeutics N/A -629.29%-173.39% Do institutionals and insiders hold more shares of AUPH or CADL? 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 16.6% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, AUPH or CADL? Aurinia Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.87, suggesting that its stock price is 187% less volatile than the S&P 500. Do analysts rate AUPH or CADL? Aurinia Pharmaceuticals presently has a consensus target price of $11.50, indicating a potential upside of 41.36%. Candel Therapeutics has a consensus target price of $21.00, indicating a potential upside of 300.76%. Given Candel Therapeutics' higher possible upside, analysts clearly believe Candel Therapeutics is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAurinia Pharmaceuticals beats Candel Therapeutics on 10 of the 17 factors compared between the two stocks. Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CADL vs. The Competition Export to ExcelMetricCandel TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$265.05M$3.10B$5.61B$8.54BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-3.0632.5927.1819.77Price / Sales2,187.83459.71411.66152.70Price / CashN/A168.6838.3234.64Price / Book11.913.376.984.63Net Income-$37.94M-$72.35M$3.24B$248.14M7 Day Performance-13.25%0.94%-0.29%-0.46%1 Month Performance-2.78%18.06%8.48%4.16%1 Year Performance-30.50%-18.20%32.16%13.35% Candel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CADLCandel Therapeutics2.9638 of 5 stars$5.24-2.2%$21.00+300.8%-29.3%$265.05M$120K-3.0660Positive NewsAUPHAurinia Pharmaceuticals3.3156 of 5 stars$8.14-0.6%$11.50+41.3%+51.0%$1.10B$247.30M-54.26300Positive NewsAnalyst RevisionWVEWave Life Sciences4.3635 of 5 stars$7.05-2.4%$21.17+200.2%+12.7%$1.09B$104.94M-6.35240Analyst ForecastAnalyst RevisionNAGENiagen Bioscience1.4744 of 5 stars$13.43+3.7%$18.00+34.0%N/A$1.06B$107.93M79.00120Analyst ForecastGap DownMLYSMineralys Therapeutics3.0739 of 5 stars$16.19+0.4%$38.00+134.7%+18.4%$1.06BN/A-4.4528Positive NewsAnalyst ForecastRCUSArcus Biosciences2.3396 of 5 stars$9.86-1.1%$24.13+144.7%-40.6%$1.04B$141M-3.13500Options VolumeAnalyst RevisionGap UpSYRESpyre Therapeutics2.3849 of 5 stars$17.16+1.1%$53.40+211.2%-52.1%$1.03B$890K-2.3073Positive NewsGap DownAKBAAkebia Therapeutics3.9728 of 5 stars$3.83-3.5%$6.75+76.2%+214.7%$1.01B$184.91M-16.65430High Trading VolumeCVACCureVac4.3061 of 5 stars$4.48+1.6%$11.00+145.5%+34.9%$1.01B$523.70M8.15880Trending NewsAnalyst ForecastOptions VolumeGap UpELVNEnliven Therapeutics2.5388 of 5 stars$20.34-1.9%$37.25+83.1%-13.6%$998.06MN/A-10.7150Insider TradeGap UpPAHCPhibro Animal Health3.7955 of 5 stars$24.23+0.6%$20.00-17.5%+37.9%$982.14M$1.19B50.481,860Positive News Related Companies and Tools Related Companies AUPH Competitors WVE Competitors NAGE Competitors MLYS Competitors RCUS Competitors SYRE Competitors AKBA Competitors CVAC Competitors ELVN Competitors PAHC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CADL) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
